Novartis has the most new approvals, but Lilly’s are worth more
When it comes to big pharma’s novel therapies, it is a case of quantity versus quality.
Brace for an end-of-year boost to drug approvals
The first half of 2022 was slow on the regulatory front, but plenty of big decisions remain for Bristol Myers Squibb, Apellis and others.
Is biopharma getting better at accelerated approval conversions?
Amid ongoing pressure to reform the FDA’s fast-track pathway, signs emerge that the criticism is being heard.
